Advances in the field of medicinal inorganic chemistry were revolutionized when the antitumor properties of cisplatin were discovered in the 1960s. In spite of the enormous success of cisplatin in treating ovarian and testicular cancers, new drugs with fewer severe side effects, reduced tumour resistance and different mechanisms of action are needed. In addition, the development of anticancer agents that are effective against many different tumours is imperative due to the staggering number of new diagnosed cases of cancer every year. Among the many early and late transition metal-based potential anticancer drugs, ruthenium (Ru) compounds have garnered a lot of interest. For example, the Ru(III) compounds NAMI-A and KP1019 are in Phase II clinical trials and several organometallic and luminescent polypyridine Ru(II) compounds have displayed high anticancer activities against several cancer cell lines. Since most of the polypyridine Ru(II) antitumor compounds contain N-donor neutral ligands, we decided to introduce new bidentate ligands into the coordination sphere. We have synthesized three (3) new monocationic polypyridine Ru(II) complexes, [Ru(bpy)2(mhp)]+ (1), [Ru(phen)2(mhp)]+ (2), [Ru(dpq)2(mhp)]+ (3), where mhp = 2-hydroxy-6-methylpyridine which were characterized by NMR, ESI-MS, electronic absorption spectroscopy and single crystal X-ray diffraction. Their anticancer properties were assessed against HELA and OVCAR-8 cancer cells and compared with that of cisplatin.

Synthesis, structural elucidation and cytotoxicity studies of ruthenium (II) polypyridine compounds with anionic N^O - donor ligands

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.